Does the media refer more to CLDX or LXRX?

In the previous week, Celldex Therapeutics had 10 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 17 mentions for Celldex Therapeutics and 7 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.83 beat Celldex Therapeutics' score of 0.74 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BCRX or LXRX?

In the previous week, BioCryst Pharmaceuticals had 3 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 10 mentions for BioCryst Pharmaceuticals and 7 mentions for Lexicon Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.13 beat Lexicon Pharmaceuticals' score of 0.83 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZBIO or LXRX?

In the previous week, Lexicon Pharmaceuticals had 2 more articles in the media than Zenas BioPharma. MarketBeat recorded 7 mentions for Lexicon Pharmaceuticals and 5 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.24 beat Lexicon Pharmaceuticals' score of 0.83 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INVA or LXRX?

In the previous week, Innoviva had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 8 mentions for Innoviva and 7 mentions for Lexicon Pharmaceuticals. Innoviva's average media sentiment score of 1.45 beat Lexicon Pharmaceuticals' score of 0.83 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LXRX or NVAX?

In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than Novavax. MarketBeat recorded 7 mentions for Lexicon Pharmaceuticals and 6 mentions for Novavax. Lexicon Pharmaceuticals' average media sentiment score of 0.83 beat Novavax's score of 0.15 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lexicon Pharmaceuticals (LXRX) Competitors

$2.33 -0.02 (-0.64%)

As of 11:45 AM Eastern

Compare

LXRX vs. CLDX, BCRX, ZBIO, INVA, and NVAX

Should you buy Lexicon Pharmaceuticals stock or one of its competitors? MarketBeat compares Lexicon Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lexicon Pharmaceuticals include Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Zenas BioPharma (ZBIO), Innoviva (INVA), and Novavax (NVAX). These companies are all part of the "biotechnology" industry.

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Celldex Therapeutics presently has a consensus price target of $54.62, suggesting a potential upside of 45.95%. Lexicon Pharmaceuticals has a consensus price target of $4.55, suggesting a potential upside of 95.70%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Celldex Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Celldex Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

In the previous week, Celldex Therapeutics had 10 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 17 mentions for Celldex Therapeutics and 7 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.83 beat Celldex Therapeutics' score of 0.74 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexicon Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$865K	3,395.57	-$258.76M	-$4.26	N/A
Lexicon Pharmaceuticals	$49.80M	20.74	-$50.34M	-$0.07	N/A

Summary

Lexicon Pharmaceuticals beats Celldex Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Lexicon Pharmaceuticals has a net margin of -37.46% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Lexicon Pharmaceuticals' return on equity of -18.64% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

In the previous week, BioCryst Pharmaceuticals had 3 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 10 mentions for BioCryst Pharmaceuticals and 7 mentions for Lexicon Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.13 beat Lexicon Pharmaceuticals' score of 0.83 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.60	$263.86M	-$1.78	N/A
Lexicon Pharmaceuticals	$49.80M	20.74	-$50.34M	-$0.07	N/A

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BioCryst Pharmaceuticals currently has a consensus target price of $20.80, indicating a potential upside of 132.01%. Lexicon Pharmaceuticals has a consensus target price of $4.55, indicating a potential upside of 95.70%. Given BioCryst Pharmaceuticals' higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

BioCryst Pharmaceuticals beats Lexicon Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Zenas BioPharma currently has a consensus target price of $44.29, indicating a potential upside of 40.41%. Lexicon Pharmaceuticals has a consensus target price of $4.55, indicating a potential upside of 95.70%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lexicon Pharmaceuticals had 2 more articles in the media than Zenas BioPharma. MarketBeat recorded 7 mentions for Lexicon Pharmaceuticals and 5 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.24 beat Lexicon Pharmaceuticals' score of 0.83 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zenas BioPharma has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Lexicon Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	199.11	-$377.74M	-$8.47	N/A
Lexicon Pharmaceuticals	$49.80M	20.74	-$50.34M	-$0.07	N/A

Zenas BioPharma has a beta of -0.96, meaning that its stock price is 196% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Summary

Lexicon Pharmaceuticals beats Zenas BioPharma on 11 of the 17 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Innoviva?

Innoviva (NASDAQ:INVA) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

In the previous week, Innoviva had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 8 mentions for Innoviva and 7 mentions for Lexicon Pharmaceuticals. Innoviva's average media sentiment score of 1.45 beat Lexicon Pharmaceuticals' score of 0.83 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Innoviva shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 2.0% of Innoviva shares are held by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Innoviva has a net margin of 119.89% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Innoviva's return on equity of 33.33% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Innoviva currently has a consensus price target of $36.20, suggesting a potential upside of 72.22%. Lexicon Pharmaceuticals has a consensus price target of $4.55, suggesting a potential upside of 95.70%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Innoviva has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$420.69M	3.69	$271.17M	$6.01	3.50
Lexicon Pharmaceuticals	$49.80M	20.74	-$50.34M	-$0.07	N/A

Innoviva has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Summary

Innoviva beats Lexicon Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Novavax?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Lexicon Pharmaceuticals presently has a consensus price target of $4.55, indicating a potential upside of 95.70%. Novavax has a consensus price target of $13.00, indicating a potential upside of 78.25%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Lexicon Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40

Lexicon Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Novavax has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market.

Novavax has a net margin of -14.73% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Novavax's return on equity of -14.82% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Novavax	-14.73%	-14.82%	1.23%

Novavax has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	20.74	-$50.34M	-$0.07	N/A
Novavax	$1.12B	1.07	$440.30M	-$0.58	N/A

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Novavax shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than Novavax. MarketBeat recorded 7 mentions for Lexicon Pharmaceuticals and 6 mentions for Novavax. Lexicon Pharmaceuticals' average media sentiment score of 0.83 beat Novavax's score of 0.15 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lexicon Pharmaceuticals and Novavax tied by winning 8 of the 16 factors compared between the two stocks.

Get Lexicon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXRX vs. The Competition

Export

Metric	Lexicon Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.04B	$3.65B	$6.86B	$12.37B
Dividend Yield	N/A	2.13%	2.65%	10.11%
P/E Ratio	-33.35	23.06	27.45	23.66
Price / Sales	20.74	212.49	495.52	78.38
Price / Cash	N/A	165.25	51.74	58.30
Price / Book	7.75	7.92	9.91	5.85
Net Income	-$50.34M	$23.81M	$3.61B	$336.64M
7 Day Performance	1.53%	-1.14%	-0.29%	0.02%
1 Month Performance	-3.12%	-7.49%	-3.96%	-5.24%
1 Year Performance	117.29%	39.62%	22.83%	17.56%

Lexicon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXRX Lexicon Pharmaceuticals	1.8617 of 5 stars	$2.33 -0.6%	$4.55 +95.7%	+129.4%	$1.04B	$49.80M	N/A	140	News Coverage Upcoming Earnings
CLDX Celldex Therapeutics	2.8668 of 5 stars	$35.42 +0.2%	$53.91 +52.2%	+68.7%	$2.77B	$1.54M	N/A	150	Upcoming Earnings Analyst Forecast
BCRX BioCryst Pharmaceuticals	3.5837 of 5 stars	$9.11 -1.9%	$20.80 +128.3%	+12.4%	$2.36B	$874.84M	N/A	530	Positive News Upcoming Earnings Short Interest Decrease
ZBIO Zenas BioPharma	3.9237 of 5 stars	$30.70 +4.0%	$44.29 +44.3%	+104.9%	$1.86B	$10M	N/A	N/A	Positive News
INVA Innoviva	3.1718 of 5 stars	$21.28 -2.0%	$36.20 +70.1%	+15.1%	$1.60B	$411.33M	3.54	100	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXRX) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. CLDX, BCRX, ZBIO, INVA, and NVAX

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Summary

How does Lexicon Pharmaceuticals compare to BioCryst Pharmaceuticals?

Summary

How does Lexicon Pharmaceuticals compare to Zenas BioPharma?

Summary

How does Lexicon Pharmaceuticals compare to Innoviva?

Summary

How does Lexicon Pharmaceuticals compare to Novavax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. CLDX, BCRX, ZBIO, INVA, and NVAX

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Do institutionals and insiders have more ownership in CLDX or LXRX?

Do analysts prefer CLDX or LXRX?

Is CLDX or LXRX more profitable?

Which has more risk & volatility, CLDX or LXRX?

Does the media refer more to CLDX or LXRX?

Which has higher valuation & earnings, CLDX or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to BioCryst Pharmaceuticals?

Is BCRX or LXRX more profitable?

Does the media refer more to BCRX or LXRX?

Which has more volatility and risk, BCRX or LXRX?

Which has higher valuation & earnings, BCRX or LXRX?

Do insiders and institutionals believe in BCRX or LXRX?

Do analysts rate BCRX or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to Zenas BioPharma?

Do analysts prefer ZBIO or LXRX?

Do institutionals and insiders hold more shares of ZBIO or LXRX?

Does the media favor ZBIO or LXRX?

Is ZBIO or LXRX more profitable?

Which has preferable valuation & earnings, ZBIO or LXRX?

Which has more risk & volatility, ZBIO or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to Innoviva?

Does the media refer more to INVA or LXRX?

Do insiders & institutionals hold more shares of INVA or LXRX?

Is INVA or LXRX more profitable?

Do analysts rate INVA or LXRX?

Which has higher valuation and earnings, INVA or LXRX?

Which has more volatility and risk, INVA or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to Novavax?

Do analysts prefer LXRX or NVAX?

Which has more volatility & risk, LXRX or NVAX?

Is LXRX or NVAX more profitable?

Which has stronger earnings & valuation, LXRX or NVAX?

Do institutionals and insiders have more ownership in LXRX or NVAX?

Does the media prefer LXRX or NVAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools